Citations

Clear

344 citation(s) found for "ASIRVATHAM, SAMUEL".

Effective Use of Percutaneous Stellate Ganglion Blockade in Patients With Electrical Storm
Tian, Ying , Wittwer, Erica D. , Xiao, Peilin , Mulpuru, Siva K. , Deshmukh, Abhishek , Lee, Hon-Chi, Ackerman, Michael J. , Asirvatham, Samuel J. , Munger, Thomas M. , Liu, Xing-Peng , Friedman, Paul A. , Cha, Yong‐Mei , Asirvatham, Samuel J , Kapa, Suraj , McLeod, Christopher J. , Noseworthy, Peter A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 13, 2019 | Volume: 12 | Issue: 9 | Pages: No page available

10.1161/circep.118.007118 | PMID 31514529 Get It

Background: Percutaneous stellate ganglion blockade (SGB) has been used for drug-refractory electrical storm due to ventricular arrhythmia (VA); however, the effects and long-term outcomes have not been well studied. Methods: This study included 30 consecutive patients who had drug-refractory electrical storm and underwent percutaneous SGB between October 1, 2013, and March 31, 2018. Bupivacaine, alone or combined with lidocaine, was injected into the neck with good local anesthetic spread in the vicinity of the left stellate ganglion (n=15) or both stellate ganglia (n=15). Data were collected for patient clinical characteristics, immediate and long-term outcomes, and procedure-related complications. Results: Clinical characteristics included age, 58±14 years; men, 73.3%; and left ventricular ejection fraction, 34±16%. At 24 hours, 60% of patients were free of VA. Patients whose VA was controlled had a lower hospital mortality rate than patients whose VA continued (5.6% versus 50.0%; P =0.009). Implantable cardioverter-defibrillator interrogation showed a significant 92% reduction in VA episodes from 26±41 to 2±4 in the 72 hours after SGB ( P <0.001). Patients who died during the same hospitalization (n=7) were more likely to have ischemic cardiomyopathy (100% versus 43.5%; P =0.03) and recurrent VA within 24 hours (85.7% versus 26.1%; P =0.009). There were no procedure-related major complications. Conclusions: SGB effectively attenuated electrical storm in more than half of patients without procedure-related complications. Percutaneous SGB may be considered for stabilizing ventricular rhythm in patients for whom other therapies have failed.
The crossroads of the left atrium
Asirvatham, Samuel J. , Ellenbogen, Kenneth A. , Asirvatham, Samuel J , Ellenbogen, Kenneth A

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 10, 2019 | Volume: 30 | Issue: 11 | Pages: 2561-2563

10.1111/jce.14148 | PMID 31502305 Get It

Cardiac memory for the clinical electrophysiologist
Siontis, Konstantinos C. , Wen, Songnan , Asirvatham, Samuel J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 3, 2019 | Volume: 30 | Issue: 10 | Pages: 2140-2143

10.1111/jce.14134 | PMID 31478287 Get It

Metabolic disturbances for the electrophysiologist
Lee, Justin Z. , Asirvatham, Samuel J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 28, 2019 | Volume: 30 | Issue: 10 | Pages: 2147-2149

10.1111/jce.14139 | PMID 31456246 Get It

Age and Sex Estimation Using Artificial Intelligence From Standard 12-Lead ECGs
Friedman, Paul A. , Ladewig, Dorothy J., Satam, Gaurav, Pellikka, Patricia A. , Munger, Thomas M. , Asirvatham, Samuel J. , Carter, Rickey E. , Asirvatham, Samuel J , Pellikka, Patricia A , Carter, Rickey E , Attia, Zachi I. , Noseworthy, Peter A. , López-Jiménez, Francisco , Scott, Christopher G. , Kapa, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 27, 2019 | Volume: 12 | Issue: 9 | Pages: No page available

10.1161/circep.119.007284 | PMID 31450977 Get It

Background: Sex and age have long been known to affect the ECG. Several biologic variables and anatomic factors may contribute to sex and age-related differences on the ECG. We hypothesized that a convolutional neural network (CNN) could be trained through a process called deep learning to predict a person’s age and self-reported sex using only 12-lead ECG signals. We further hypothesized that discrepancies between CNN-predicted age and chronological age may serve as a physiological measure of health. Methods: We trained CNNs using 10-second samples of 12-lead ECG signals from 499 727 patients to predict sex and age. The networks were tested on a separate cohort of 275 056 patients. Subsequently, 100 randomly selected patients with multiple ECGs over the course of decades were identified to assess within-individual accuracy of CNN age estimation. Results: Of 275 056 patients tested, 52% were males and mean age was 58.6±16.2 years. For sex classification, the model obtained 90.4% classification accuracy with an area under the curve of 0.97 in the independent test data. Age was estimated as a continuous variable with an average error of 6.9±5.6 years (R-squared =0.7). Among 100 patients with multiple ECGs over the course of at least 2 decades of life, most patients (51%) had an average error between real age and CNN-predicted age of <7 years. Major factors seen among patients with a CNN-predicted age that exceeded chronologic age by >7 years included: low ejection fraction, hypertension, and coronary disease ( P <0.01). In the 27% of patients where correlation was >0.8 between CNN-predicted and chronologic age, no incident events occurred over follow-up (33±12 years). Conclusions: Applying artificial intelligence to the ECG allows prediction of patient sex and estimation of age. The ability of an artificial intelligence algorithm to determine physiological age, with further validation, may serve as a measure of overall health.
Purkinje tissue modification and ventricular fibrillation
Asirvatham, Samuel J. , Asirvatham, Samuel J , DeSimone, Christopher V.

Mayo Clinic

Pacing and Clinical Electrophysiology | August 13, 2019 | Volume: 42 | Issue: 10 | Pages: 1291-1293

10.1111/pace.13781 | PMID 31407803 Get It

Outcome of combined cryo‐ and radiofrequency‐catheter ablation in patients with supraventricular tachycardias
Miyamoto, Koji , Mulpuru, Siva K. , Deshmukh, Abhishek , Asirvatham, Samuel J. , Munger, Thomas M. , Friedman, Paul A. , Packer, Douglas L. , Kapa, Suraj , Mulpuru, Siva K , Asirvatham, Samuel J , Friedman, Paul A , Kapa, Suraj

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 16, 2019 | Volume: 30 | Issue: 10 | Pages: 1960-1966

10.1111/jce.14068 | PMID 31310387 Get It

AbstractBackgroundThere are few data regarding the outcome of a combined cryo‐ and radiofrequency (RF)‐catheter ablation of various types of supraventricular tachycardias (SVTs) originating from near the normal conduction system.METHODSWe analyzed all patients undergoing combined cryo‐ and RF‐ catheter ablation at Mayo Clinic, Rochester, MN as part of the ablation of SVTs with potential risks of injury to the normal conduction system. This study aimed to assess the outcome of a combined cryo‐ and RF‐catheter ablation of various types of SVTs.RESULTSThe study population consisted of 54 patients (38 ± 17 years, 32 men). A combined cryo‐ and RF‐catheter ablation was attempted for septal accessary pathways (APs) in 26, atrioventricular nodal reentrant tachycardia (AVNRT) in 14, atrial tachycardia (AT) in 7, and junctional ectopic tachycardia in 7 patients. Forty‐one patients (76%) were successfully ablated with cryoablation, and RF ablation after an unsuccessful cryoablation ablated the SVTs successfully at the same location in 6 patients (11%). Complication occurred in 1 patient (deep vein thrombosis). The cumulative freedom from SVT rate at 30 days after the procedure was 78% and there was no significant difference in the recurrence rate among the SVTs.CONCLUSIONA combined cryo‐ and RF‐catheter ablation is clinically effective in patients undergoing SVT ablation with the potential risk of injury to the normal conduction system.
Epicardial access: Adjusting the approach as we discover complications
Vaidya, Vaibhav R. , Asirvatham, Samuel J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 21, 2019 | Volume: 30 | Issue: 8 | Pages: 1341-1344

10.1111/jce.14036 | PMID 31222891 Get It

Electrophysiologic effects and outcomes of sympatholysis in patients with recurrent ventricular arrhythmia and structural heart disease
Cai, Cheng , Dai, Mingyan , Tian, Ying , Zhang, Pei , Wittwer, Erica D. , Rho, Richard H., Mulpuru, Siva K. , Lee, Hon‐Chi, Ackerman, Michael J. , Asirvatham, Samuel J. , Munger, Thomas M. , Friedman, Paul A. , Cha, Yong‐Mei , Dai, Ming-Yan, Kapa, Suraj , Mulpuru, Siva K , Asirvatham, Samuel J , Chen, Ming-Long , Friedman, Paul A , Cha, Yong-Mei , Kapa, Suraj , McLeod, Christopher J.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 14, 2019 | Volume: 30 | Issue: 9 | Pages: 1499-1507

10.1111/jce.14030 | PMID 31199536 Get It

AbstractIntroductionAutonomic modulation has been used as a therapy to control recurrent ventricular arrhythmia (VA). This study was to explore stellate ganglion block (SGB) effect on cardiac electrophysiologic properties and evaluate the long‐term outcome of cardiac sympathetic denervation (CSD) for patients with recurrent VA and structural heart disease (SHD).Materials and MethodsPatients who had recurrent VA due to SHD were enrolled prospectively. Electrophysiologic study and ventricular tachycardia (VT) induction were performed before and after left and right SGB. VA burden and long‐term outcomes were assessed for a separate patient group who underwent left or bilateral CSD for drug‐refractory VA due to SHD.ResultsElectrophysiologic study of nine patients showed that baseline mean (SD) corrected sinus node recovery time (cSNRT) increased from 320.4 (73.3) ms to 402.9 (114.2) ms after left and 482.4 (95.7) ms after bilateral SGB (P = .03). SGB did not significantly change P‐R, QRS, and Q‐T intervals and ventricular effective refractory period, nor did the inducibility of VA. Nineteen patients underwent left (n = 14) or bilateral (n = 5) CSD. CSD reduced VA burden and appropriate ICD therapies from a median (interquartile range) of 2.5 (0.4‐11.6) episodes weekly to 0.1 (0.0‐2.4) episodes weekly at 6‐month follow‐up (P = .002). Three‐year freedom from orthotopic heart transplant (OHT) and death was 52.6%. New York Heart Association functional class III/IV and VT rate less than 160 beats per minute were predictors of recurrent VA, OHT, and death.ConclusionSGB increased cSNRT without changing heart rate. CSD was more beneficial for patients with mild‐to‐moderate heart failure and faster VA.
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction
Lee, Justin Z. , Amin, Mustapha, Neville, Matthew R., Almader‐Douglas, Diana , Killu, Ammar M. , Madhavan, Malini , Cha, Yong‐Mei , Asirvatham, Samuel J. , Friedman, Paul A. , Mulpuru, Siva K. , Tseng, Andrew S. , Kunze, Katie L. , Almader-Douglas, Diana, Asirvatham, Samuel J , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 4, 2019 | Volume: 12 | Issue: 6 | Pages: No page available

10.1161/circep.118.006951 | PMID 31159582 Get It

Background: The treatment of heart failure with reduced ejection fraction has been the subject of numerous randomized controlled trials involving medications and cardiac implantable electronic device therapies. As newer effective pharmacological therapies suggest significant reductions in all-cause mortality, the role of additional device therapy in heart failure with reduced ejection fraction deserves further scrutiny. Methods: A systematic review and network meta-analysis on the effect of medication and device therapies in heart failure with reduced ejection fraction on all-cause mortality was performed. Randomized controlled trials published between January 1980 and July 2017 were identified using Medline, EMBASE, and Cochrane Controlled Register of Trials databases. Pcnetmeta package in R was used to calculate treatment arm–based estimated rates, rate ratios, and probability ranks with 95% credible intervals. Results: Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with β-blockers (BBs) alone or in addition to implantable cardiac defibrillators or cardiac resynchronization therapy with defibrillators demonstrated a significant reduction of all-cause mortality when compared with placebo. By probability rank, implantable cardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid receptor antagonist, implantable cardiac defibrillator+ACE inhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist combination therapies have the highest probability of being ranked the best treatment. There was no significant difference in the rate of mortality when comparing angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist to implantable cardiac defibrillator+optimal pharmacological combination therapy. Conclusions: BB and renin-angiotensin system blockers alone or in combination with defibrillator device therapy have robust evidence for a reduction in mortality compared with placebo. The comparative efficacy of pharmacological therapy with angiotensin receptor-neprilysin inhibitors and device therapy deserves further investigation.